Ablatherm-HIFU Featured in Eight Presentations at World Congress of Endourology (WCE) Ablatherm-HIFU Focal Treatment Advantages Showcased at First Montreal Conference on Focal Therapy LYON, France , Dec. 8, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
LYON, France , Aug. 17, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided an update regarding its Ablatherm-HIFU ( High Intensity Focused Ultrasound ) ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer.
LYON, France , March 20, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has completed its response to questions from the FDA regarding the Company's Ablatherm-HIFU Pre-Market Approval ("PMA") application, closing this step
Responds to Gastroenterology and Urology Devices Panel Vote on Ablatherm-HIFU for Treatment of Prostate Cancer LYON, France , Aug. 5, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided comments on the recent Gastroenterology and Urology
EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. LYON, France , March 6, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the appointment of Noah J. Bartsch as Vice President of Global Medical, Regulatory, and
LYON, France, Jun 26, 2009 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Dr. Argil J. Wheelock, MD was appointed to its Board of Directors, effective June 25, 2009. Dr. Wheelock replaces Dr.